Pages that link to "Q81123125"

The following pages link to Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease (Q81123125):

Displaying 23 items.

• Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease (Q33564175) (← links)
• Anaphylaxis avoidance and management: educating patients and their caregivers (Q33895403) (← links)
• Need for infliximab dose intensification in Crohn's disease and ulcerative colitis (Q33958740) (← links)
• Infliximab in the treatment of plaque type psoriasis (Q34620291) (← links)
• Infliximab therapy in pediatric Crohn's disease: a review (Q35026358) (← links)
• Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa (Q35250578) (← links)
• Biologics in paediatric Crohn's disease (Q35579308) (← links)
• Infliximab therapy in children and adolescents with inflammatory bowel disease (Q36903742) (← links)
• Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease (Q37609746) (← links)
• Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis (Q38059422) (← links)
• Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis (Q38080683) (← links)
• Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response (Q38118313) (← links)
• Safety of TNF inhibitors in adolescents and children (Q38193792) (← links)
• Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children (Q38291356) (← links)
• Use of anti-TNF drug levels to optimise patient management (Q38608951) (← links)
• Test accuracy of drug and antibody assays for predicting response to antitumour necrosis factor treatment in Crohn's disease: a systematic review and meta-analysis (Q38695300) (← links)
• Stability of infliximab in polyvinyl chloride bags (Q38759515) (← links)
• Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease (Q38919270) (← links)
• Assays for measurement of TNF antagonists in practice. (Q45987984) (← links)
• Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response (Q83833027) (← links)
• Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease (Q86264935) (← links)
• Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients (Q92170817) (← links)
• Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events (Q92626116) (← links)